1
|
Mowat Y, Hoad V, Masser B, Kaldor J, Heywood A, Thorpe R, McManus H, McGregor S, Haire B. The impact of blood donation deferral strategies on the eligibility of men who have sex with men and other sexual risk behavior in Australia. Transfusion 2024; 64:493-500. [PMID: 38348786 DOI: 10.1111/trf.17732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 01/10/2024] [Accepted: 01/11/2024] [Indexed: 02/27/2024]
Abstract
BACKGROUND In Australia, a man cannot donate blood if he has had sex with another man within the past 3 months. However, this policy has been criticized as being discriminatory as it does not consider lower risk subgroups, and led to calls for modifications to the policy that more accurately distinguish risk among gay, bisexual, and other men who have sex with men (GBM). STUDY DESIGN AND METHODS We used data from a nationally representative survey to estimate the proportion of GBM aged 18-74 years old who would be eligible to donate under current criteria and other scenarios. RESULTS Among the 5178 survey participants, 155 (3.0%) were classified as GBM based on survey responses, Among the GBM, 40.2% (95% CI 28.0%-53.7%) were eligible to donate based on current criteria, and 21.0% (95% CI 14.5%-29.5%) were ineligible due to the 3 months deferral alone. Eligibility among GBM, all men, and the population increased as criteria were removed. Under the new Australian plasma donation criteria, 73.6% (95% CI 64.4%-81.1%) of GBM, 68.4% (95% CI 65.5%-71.2%) of all men, and 60.8% (95% CI 58.8%-62.8%) of the full population were estimated to be eligible. Only 16.1% (95% CI 8.6%-28.1%) of GBM knew that the male-to-male sex deferral period is 3 months. DISCUSSION Changing the deferral criteria and sexual risk evaluation would lead to a higher proportion of GBM being eligible to donate blood. Knowledge of the current GBM deferral period is very low. Improved education about the current criteria and any future changes are required to improve blood donation rates.
Collapse
Affiliation(s)
- Yasmin Mowat
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Veronica Hoad
- Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Barbara Masser
- Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
- School of Psychology, The University of Queensland, Brisbane, Queensland, Australia
| | - John Kaldor
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Anita Heywood
- School of Population Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Rachel Thorpe
- Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Hamish McManus
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Skye McGregor
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Bridget Haire
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| |
Collapse
|
2
|
Winkler NE, Koirala A, Kaur G, Prasad S, Hirani R, Baker J, Hoad V, Gosbell IB, Irving DO, Hueston L, O'Sullivan MV, Kok J, Dwyer DE, Macartney K. Seroprevalence of Japanese encephalitis virus-specific antibodies in Australia following novel epidemic spread: protocol for a national cross-sectional study. BMJ Open 2024; 14:e075569. [PMID: 38326269 PMCID: PMC10860057 DOI: 10.1136/bmjopen-2023-075569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 11/08/2023] [Indexed: 02/09/2024] Open
Abstract
INTRODUCTION Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes encephalitis and other morbidity in Southeast Asia. Since February 2022, geographically dispersed JEV human, animal and vector detections occurred on the Australian mainland for the first time. This study will determine the prevalence of JEV-specific antibodies in human blood with a focus on populations at high risk of JEV exposure and determine risk factors associated with JEV seropositivity by location, age, occupation and other factors. METHOD Samples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses. ANALYSIS Two analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model. ETHICS National Mutual Acceptance ethical approval was obtained from the Sydney Children's Hospitals Network Human Research Ethics Committee (HREC). Local approvals were sought in each jurisdiction. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC. DISSEMINATION Findings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations.
Collapse
Affiliation(s)
- Noni Ella Winkler
- National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia
| | - Archana Koirala
- National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Guddu Kaur
- National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia
- National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Shayal Prasad
- National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia
| | - Rena Hirani
- Australian Red Cross Lifeblood, Sydney, New South Wales, Australia
- Faculty of Science and Engineering, Macquarie University, Macquarie Park, New South Wales, Australia
| | - Jannah Baker
- The University of Sydney, Sydney, New South Wales, Australia
| | - Veronica Hoad
- Australian Red Cross Lifeblood, Perth, Western Australia, Australia
| | - Iain B Gosbell
- Australian Red Cross Lifeblood, Sydney, New South Wales, Australia
- School of Medicine, Western Sydney University, Penrith South DC, New South Wales, Australia
| | - David O Irving
- Australian Red Cross Lifeblood, Sydney, New South Wales, Australia
- Faculty of Health, University of Technology Sydney, Broadway, New South Wales, Australia
| | - Linda Hueston
- New South Wales Health Pathology - Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
- Griffith University Menzies Health Institute Queensland, Brisbane, Queensland, Australia
| | - Matthew Vn O'Sullivan
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- New South Wales Health Pathology - Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
| | - Jen Kok
- New South Wales Health Pathology - Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
| | - Dominic E Dwyer
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- New South Wales Health Pathology - Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
| | - Kristine Macartney
- National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
3
|
Mowat Y, Hoad V, Haire B, Masser B, Kaldor J, Heywood A, Thorpe R, McManus H, McGregor S. Prevalence of blood donation eligibility in Australia: A population survey. Transfusion 2023; 63:1519-1527. [PMID: 37464879 PMCID: PMC10952191 DOI: 10.1111/trf.17474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Revised: 05/25/2023] [Accepted: 05/26/2023] [Indexed: 07/20/2023]
Abstract
BACKGROUND Reliable estimates of the population proportion eligible to donate blood are needed by blood collection agencies to model the likely impact of changes in eligibility criteria and inform targeted population-level education, recruitment, and retention strategies. In Australia, the sole estimate was calculated 10+ years ago. With several subsequent changes to the eligibility criteria, an updated estimate is required. STUDY DESIGN AND METHODS We conducted a cross-sectional national population survey to estimate eligibility for blood donation. Respondents were aged 18+ and resident in Australia. Results were weighted to obtain a representative sample of the population. RESULTS Estimated population prevalence of blood donation eligibility for those aged 18-74 was 57.3% (95% CI 55.3-59.3). The remaining 42.7% (95% CI 40.7-44.7) were either temporarily (25.3%, 95% CI 23.5-27.2) or permanently ineligible (17.4%, 95% CI 16.1-18.9). Of those eligible at the time of the survey, that is, with the UK geographic deferral for variant Creutzfeldt-Jakob disease included, (52.9%, 95% CI 50.8-54.9), 14.2% (95% CI 12.3-16.3) reported donating blood within the previous 2 years. Eligibility was higher among men (62.6%, 95% CI 59.6-65.6) than women (52.8%, 95% CI 50.1-55.6). The most common exclusion factor was iron deficiency/anemia within the last 6 months; 3.8% (95% CI 3.2-4.6) of the sample were ineligible due to this factor alone. DISCUSSION We estimate that approximately 10.5 million people (57.3% of 18-74-year-olds) are eligible to donate blood in Australia. Only 14.2% of those eligible at the time of survey reported donating blood within the previous 2 years, indicating a large untapped pool of potentially eligible blood donors.
Collapse
Affiliation(s)
- Yasmin Mowat
- The Kirby InstituteUniversity of New South WalesSydneyAustralia
| | | | - Bridget Haire
- The Kirby InstituteUniversity of New South WalesSydneyAustralia
| | - Barbara Masser
- Australian Red Cross LifebloodMelbourneAustralia
- School of PsychologyThe University of QueenslandBrisbaneAustralia
| | - John Kaldor
- The Kirby InstituteUniversity of New South WalesSydneyAustralia
| | - Anita Heywood
- School of Population HealthUniversity of New South WalesSydneyAustralia
| | | | - Hamish McManus
- The Kirby InstituteUniversity of New South WalesSydneyAustralia
| | - Skye McGregor
- The Kirby InstituteUniversity of New South WalesSydneyAustralia
| |
Collapse
|
4
|
Clifford V, Klein LD, Brown R, Sulfaro C, Hoad V, Gosbell IB, Pink J. Donor and recipient safety in human milk banking. J Paediatr Child Health 2022; 58:1629-1634. [PMID: 35779010 DOI: 10.1111/jpc.16066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 05/01/2022] [Accepted: 06/08/2022] [Indexed: 11/26/2022]
Abstract
AIM Australian Red Cross Lifeblood supplies pasteurised donor human milk (PDHM) to more than 30 partner hospitals across Australia. Preterm infants who receive PDHM are a highly vulnerable population but formal biovigilance programs are rare in human milk banking. Lifeblood Milk performs ongoing surveillance for both donor and recipient adverse events. This study aimed to formally review adverse events reported to Lifeblood Milk since 2018. METHODS Milk donor infectious diseases testing outcomes and donor adverse events (DAEs) are prospectively recorded at Lifeblood. Infant recipient adverse events are contractually reported back to Lifeblood Milk by hospitals and assessed according to severity and likelihood of relationship to PDHM administration. Donor and recipient adverse events over a 3.5-year period (July 2018 to December 2021) were reviewed. RESULTS There were three DAEs (3/976 = 0.31%) related to phlebotomy; these included two vasovagal reactions and one phlebotomy site haematoma. Eight (8/976 = 0.81%) additional donors had biological false reactive (BFR) infectious diseases serology results. There were 10 reported suspected adverse events in recipients. Six were infection-related; other events included milk curd obstruction, high urinary iodine levels, sudden cardiac death and nasogastric tube obstruction. All reported suspected adverse events in recipients were classified as unlikely to be related, or definitely not related, to PDHM administration. CONCLUSIONS Milk donor adverse events were rare but biological false reactive serology results were not uncommon. There were no recipient adverse events considered causally related to pasteurised donor human milk, which is generally a low-risk biological product. Ongoing biovigilance remains essential.
Collapse
Affiliation(s)
- Vanessa Clifford
- Clinical Services and Research and Business Growth & Innovation, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
- Department of Laboratory Services, Royal Children's Hospital, Melbourne, Victoria, Australia
- Department of Infection and Immunity, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
| | - Laura D Klein
- Clinical Services and Research and Business Growth & Innovation, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
- Departent of Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia
| | - Richard Brown
- Clinical Services and Research and Business Growth & Innovation, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Christine Sulfaro
- Clinical Services and Research and Business Growth & Innovation, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Veronica Hoad
- Clinical Services and Research and Business Growth & Innovation, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Iain B Gosbell
- Clinical Services and Research and Business Growth & Innovation, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
- School of Medicine, Western Sydney University, Penrith, New South Wales, Australia
| | - Joanne Pink
- Clinical Services and Research and Business Growth & Innovation, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| |
Collapse
|
5
|
Hirani R, Hoad V, Gosbell IB, Irving DO. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors. Transfusion 2021; 62:292-297. [PMID: 34936102 DOI: 10.1111/trf.16781] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 12/08/2021] [Accepted: 12/08/2021] [Indexed: 01/09/2023]
Abstract
BACKGROUND Several studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A individuals are over-represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS-CoV-2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS-CoV-2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors. STUDY DESIGN AND METHODS ABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay. RESULTS The distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over-represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872). CONCLUSION ABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS-CoV-2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group.
Collapse
Affiliation(s)
- Rena Hirani
- Clinical Services and Research, Australian Red Cross Lifeblood, Australia.,Department of Molecular Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, Australia
| | - Veronica Hoad
- Clinical Services and Research, Australian Red Cross Lifeblood, Australia
| | - Iain B Gosbell
- Clinical Services and Research, Australian Red Cross Lifeblood, Australia.,School of Medicine, Western Sydney University, Penrith, Australia
| | - David O Irving
- Clinical Services and Research, Australian Red Cross Lifeblood, Australia.,Faculty of Nursing, Midwifery & Health, University of Technology Sydney, Sydney, Australia
| |
Collapse
|
6
|
Al-Riyami AZ, Burnouf T, Yazer M, Triulzi D, Kumaş LT, Sağdur L, Pelit NB, Bazin R, Hindawi SI, Badawi MA, Patidar GK, Pandey HC, Chaurasia R, Fachini RM, Scuracchio P, Wendel S, Ang AL, Ong KH, Young P, Ihalainen J, Vierikko A, Qiu Y, Yang R, Xu H, Rahimi-Levene N, Shinar E, Izak M, Gonzalez CA, Ferrari DM, Cini PV, Aditya RN, Sharma RR, Sachdev S, Hans R, Lamba DS, Nissen-Meyer LSH, Devine DV, Lee CK, Leung JNS, Hung IFN, Tiberghien P, Gallian P, Morel P, Al Maamari K, Al-Hinai Z, Vrielink H, So-Osman C, De Angelis V, Berti P, Ostuni A, Marano G, Nevessignsky MT, El Ekiaby M, Daly J, Hoad V, Kim S, van den Berg K, Vermeulen M, Glatt TN, Schäfer R, Reik R, Gammon R, Lopez M, Estcourt L, MacLennan S, Roberts D, Louw V, Dunbar N. International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary. Vox Sang 2021; 116:1117-1135. [PMID: 34013968 PMCID: PMC8242386 DOI: 10.1111/vox.13113] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 04/07/2021] [Indexed: 12/27/2022]
Affiliation(s)
| | - Thierry Burnouf
- College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Nancy Dunbar
- Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
| | | |
Collapse
|
7
|
Al-Riyami AZ, Burnouf T, Yazer M, Triulzi D, Kumaş LT, Sağdur L, Pelit NB, Bazin R, Hindawi SI, Badawi MA, Patidar GK, Pandey HC, Chaurasia R, Fachini RM, Scuracchio P, Wendel S, Ang AL, Ong KH, Young P, Ihalainen J, Vierikko A, Qiu Y, Yang R, Xu H, Rahimi-Levene N, Shinar E, Izak M, Gonzalez CA, Ferrari DM, Cini PV, Aditya RN, Sharma RR, Sachdev S, Hans R, Lamba DS, Nissen-Meyer LSH, Devine DV, Lee CK, Leung JNS, Hung IFN, Tiberghien P, Gallian P, Morel P, Al Maamari K, Al-Hinai Z, Vrielink H, So-Osman C, De Angelis V, Berti P, Ostuni A, Marano G, Nevessignsky MT, El Ekiaby M, Daly J, Hoad V, Kim S, van den Berg K, Vermeulen M, Glatt TN, Schäfer R, Reik R, Gammon R, Lopez M, Estcourt L, MacLennan S, Roberts D, Louw V, Dunbar N. International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses. Vox Sang 2021; 116:e71-e120. [PMID: 34013981 PMCID: PMC8242651 DOI: 10.1111/vox.13114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 04/07/2021] [Indexed: 01/09/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | - Salwa I Hindawi
- King Abdulaziz University and King Abdulaziz University Hospital, Jeddah, Saudi Arabia
| | - Maha A Badawi
- King Abdulaziz University and King Abdulaziz University Hospital, Jeddah, Saudi Arabia
| | | | | | | | | | | | | | - Ai Leen Ang
- Health Sciences Authority, Singapore City, Singapore
| | - Kiat Hoe Ong
- Tan Tock Seng Hospital, Singapore City, Singapore
| | | | | | | | - Yan Qiu
- Beijing Red Cross Blood Centre, Beijing, China
| | - Ru Yang
- Wuhan Blood Centre, Wuhan, China
| | - Hua Xu
- Shaanxi Blood Center, Shaanxi, China
| | | | - Eilat Shinar
- Magen David Adom National Blood Services, Tel Aviv, Israel
| | - Marina Izak
- Magen David Adom National Blood Services, Tel Aviv, Israel
| | | | | | | | - Robby Nur Aditya
- Central Blood Transfusion Service Indonesia Red Cross (PMI), Jakarta, Indonesia
| | - Ratti Ram Sharma
- Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Suchet Sachdev
- Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Rekha Hans
- Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Divjot Singh Lamba
- Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | | | | | - Cheuk Kwong Lee
- Hong Kong Red Cross Blood Transfusion Service, Hong Kong SAR, China
| | | | - Ivan Fan Ngai Hung
- Department of Medicine, the University of Hong Kong, Hong Kong SAR, China
| | | | - Pierre Gallian
- Etablissement Français du Sang, La Plaine St Denis, France
| | - Pascal Morel
- Etablissement Français du Sang, La Plaine St Denis, France
| | | | - Zaid Al-Hinai
- Sultan Qaboos University Hospital, Seeb, Sultanate of Oman
| | | | | | | | - Pierluigi Berti
- Italian Society for Hemapheresis cell Manipulation (SIdEM), Bari, Italy
| | - Angelo Ostuni
- Italian Society for Hemapheresis cell Manipulation (SIdEM), Bari, Italy
| | | | | | | | - James Daly
- Australian Red Cross Lifeblood, Melbourne, Vic., Australia
| | - Veronica Hoad
- Australian Red Cross Lifeblood, Melbourne, Vic., Australia
| | - Sinyoung Kim
- Yonsei University College of Medicine, Seoul, South Korea
| | - Karin van den Berg
- South African National Blood Service, University of Cape Town, Cape Town, South Africa
| | - Marion Vermeulen
- South African National Blood Service, University of Cape Town, Cape Town, South Africa
| | - Tanya Nadia Glatt
- South African National Blood Service, University of Cape Town, Cape Town, South Africa
| | - Richard Schäfer
- German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Frankfurt, Germany
| | | | | | | | | | | | | | - Vernon Louw
- Western Cape Blood Service, Cape Town, South Africa
| | | |
Collapse
|
8
|
Clifford V, Klein LD, Sulfaro C, Karalis T, Hoad V, Gosbell I, Pink J. What are Optimal Bacteriological Screening Test Cut-Offs for Pasteurized Donor Human Milk Intended for Feeding Preterm Infants? J Hum Lact 2021; 37:43-51. [PMID: 33351688 DOI: 10.1177/0890334420981013] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND Definitive criteria for microbial screening of pasteurized donor human milk are not well established and international recommendations vary. AIMS (1) To review pasteurized donor human milk batch discard due to failed microbial screening criteria at our milk bank (following United Kingdom National Institute of Clinical Excellence guidelines), and (2) to compare our known milk discard proportion with estimated milk discard proportions that would be required by other international milk bank guidelines. METHODS We reviewed our microbial screening results (N = 783) over 18-months (July 2018-December 2019) and compared our known milk discard proportion with estimated milk discard proportions using other international milk bank guidelines. RESULTS Of samples, n = 50 (6.4%) failed pre-pasteurization screening, most commonly due to the presence of >104 CFU/mL Enterobacterales in the pre-pasteurization sample (n = 30; 3.8%). Two (0.3%) samples failed post-pasteurization screening, with Bacillus cereus identified in both cases, resulting in total discard proportion of 6.7% (n = 52) of batches. Applying European Milk Bank Association recommended bacterial screening criteria, approximately 23.3% (n = 183) of milk batches would have been discarded. CONCLUSIONS Further research is required to justify the stringent European Milk Bank Association recommendations for pre-pasteurization discard criteria, although we believe that a post-pasteurization acceptance criterion of <1 CFU/mL is appropriate and aligns with international guidance. Further work is needed to understand pasteurized donor human milk microbiological safety risks, to better integrate screening criteria within current food standards regulation, and to consider risk-based assessment including the impact on availability and affordability.
Collapse
Affiliation(s)
- Vanessa Clifford
- 216919 Australian Red Cross Lifeblood, Australia.,Murdoch Children's Research Institute, Flemington Rd, Parkville, VIC, Australia.,School of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia
| | | | | | - Tass Karalis
- Dairy Technical Services Food Assurance, Silverwater, NSW, Australia
| | | | - Iain Gosbell
- 216919 Australian Red Cross Lifeblood, Australia.,School of Medicine, Western Sydney University, Penrith, NSW, Australia
| | - Joanne Pink
- 216919 Australian Red Cross Lifeblood, Australia
| |
Collapse
|
9
|
Masser BM, Ferguson E, Thorpe R, Lawrence C, Davison TE, Hoad V, Gosbell IB. Motivators of and barriers to becoming a COVID-19 convalescent plasma donor: A survey study. Transfus Med 2020; 31:176-185. [PMID: 33368777 DOI: 10.1111/tme.12753] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Revised: 12/12/2020] [Accepted: 12/14/2020] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To determine the motivators and barriers to COVID-19 convalescent plasma donation by those in the United Kingdom who have been diagnosed with or who have had symptoms of SARS-CoV-2 (COVID-19) but who have not donated. BACKGROUND Convalescent plasma from people recovered from COVID-19 with sufficient antibody titres is a potential option for the treatment and prevention of COVID-19. However, to date, recruiting and retaining COVID-19 convalescent plasma donors has been challenging. Understanding why those eligible to donate COVID-19 convalescent plasma have not donated is critical to developing recruitment campaigns. METHODS/MATERIALS A total of 419 UK residents who indicated that they had been infected with COVID-19 and who lived within 50 km of sites collecting COVID-19 convalescent plasma completed an online survey between 25th June and 5th July 2020. Respondents completed items assessing their awareness of convalescent plasma, motivations and barriers to donation and intention to donate COVID-19 convalescent plasma. RESULTS Awareness of COVID-19 convalescent plasma was low. Exploratory factor analysis identified six motivations and seven barriers to donating. A stronger sense of altruism through adversity and moral and civic duty were positively related to intention to donate, whereas generic donation fears was negatively related. CONCLUSIONS Once potential donors are aware of convalescent plasma, interventions should focus on the gratitude and reciprocity that those eligible to donate feel, along with a focus on (potentially) helping family and norms of what people ought to do. Fears associated with donation should not be neglected, and strategies that have been successfully used tor recruit whole-blood donors should be adapted and deployed to recruit COVID-19 convalescent plasma donors.
Collapse
Affiliation(s)
- Barbara M Masser
- School of Psychology, The University of Queensland, St Lucia, Queensland, Australia.,Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Eamonn Ferguson
- School of Psychology, University of Nottingham, Nottingham, UK
| | - Rachel Thorpe
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Claire Lawrence
- School of Psychology, University of Nottingham, Nottingham, UK.,Lawrence Psych Advisory, Nottingham, UK
| | - Tanya E Davison
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Veronica Hoad
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Iain B Gosbell
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.,School of Medicine, Western Sydney University, Sydney, New South Wales, Australia
| |
Collapse
|
10
|
Clifford V, Sulfaro C, Lee J, Pink J, Hoad V. Development and evaluation of formal guidelines for donor selection for human milk banks. J Paediatr Child Health 2020; 56:1242-1248. [PMID: 32364330 DOI: 10.1111/jpc.14909] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 02/26/2020] [Accepted: 03/24/2020] [Indexed: 11/26/2022]
Abstract
AIM Donor selection for milk banks is essential to ensure the safety and nutritional quality of the donor milk, and to ensure that the prospective donor and her breastfeeding infant do not come to harm through donating. Australian Red Cross Lifeblood Milk went through a robust process to develop a set of criteria for the selection and screening of potential breast milk donors, which included development of a Donor Questionnaire (DQ), supported by a formal set of Guidelines for the Selection of Milk Donors. Key screening questions from the DQ were made available to prospective donors to self-screen prior to the formal assessment process. The aim of this study was to review the outcomes of milk donor screening at Lifeblood Milk. METHODS We reviewed the outcomes of our donor screening process over the first 12-months (July 2018-June 2019) of operations. RESULTS A total of 50 out of 327 donors who responded to the self-screening questions were not able to proceed further; 201 donors were formally screened using the DQ and Guidelines for the Selection of Milk Donors, with 9 of 201 deferred based on their responses. An additional two donors were deferred (failed phlebotomy (n = 1) and reactive infectious disease serology (n = 1)), with 190 of 201 (95%) of prospective donors accepted after screening. CONCLUSIONS Our experience highlighted international differences in practice between milk banks and lack of strong research to inform milk donor selection. Making a set of key screening questions available to donors for self-screening resulted in a high acceptance rate (95%) for donors who began the formal screening process. Further work is needed to better understand the impact of deferral on prospective milk donors.
Collapse
Affiliation(s)
- Vanessa Clifford
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.,Department of Microbiology, Laboratory Services, Royal Children's Hospital, Melbourne, Victoria, Australia
| | - Christine Sulfaro
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - June Lee
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Joanne Pink
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| | - Veronica Hoad
- Clinical Services and Research, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
| |
Collapse
|
11
|
Thijsen A, Davison TE, Speedy J, Hoad V, Masser B. Offering new and returned donors the option to give plasma: implications for donor retention and donor adverse events. Vox Sang 2020; 116:273-280. [PMID: 32702163 DOI: 10.1111/vox.12977] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Revised: 06/22/2020] [Accepted: 06/24/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND OBJECTIVES In 2018, Australian Red Cross Lifeblood changed its plasmapheresis eligibility criteria to allow donors to donate plasma without the requirement of a prior successful whole blood donation. This study evaluated the impact of this policy change on donor retention and donor safety. MATERIALS AND METHODS All donors who had attempted to give their first plasma or whole blood donation from January to June 2018 were included in this retrospective cohort study. Donor characteristics and adverse events were analysed for this index donation, and the cohort was followed for 18 months to analyse time to return, subsequent donation frequency and predictors of return. RESULTS Male and younger donors provided a significantly greater proportion of first donation plasma than females and older donors. New donors who gave plasma had the highest rate of donor adverse events, including vasovagal reactions and phlebotomy injuries. Nevertheless, donor retention was not affected, with more new donors returning and at a greater subsequent donation frequency after a plasma donation compared to new donors donating whole blood. First-time plasma donors who had previously donated whole blood, however, had greater and quicker rates of return, and more subsequent donations. CONCLUSION Offering new donors the option to give plasma had a positive effect on donor return and subsequent donation frequency. Removing the requirement of a prior whole blood donation is a viable way to increase plasma collections although the combined effect of new donor status and plasmapheresis procedure on adverse event risk needs to be considered.
Collapse
Affiliation(s)
- Amanda Thijsen
- Clinical Services and Research, Australian Red Cross Lifeblood, Sydney, NSW, Australia
| | - Tanya E Davison
- Clinical Services and Research, Australian Red Cross Lifeblood, Sydney, NSW, Australia
| | - Joanna Speedy
- Clinical Services and Research, Australian Red Cross Lifeblood, Sydney, NSW, Australia
| | - Veronica Hoad
- Clinical Services and Research, Australian Red Cross Lifeblood, Sydney, NSW, Australia
| | - Barbara Masser
- Clinical Services and Research, Australian Red Cross Lifeblood, Sydney, NSW, Australia.,School of Psychology, The University of Queensland, Brisbane, QLD, Australia
| |
Collapse
|
12
|
Clackett S, Seed CR, Prestage G, Hammoud MA, Hoad V, Saxton P, Haire B, Holt M, Jin F, Bourne A, Maher L, Kaldor J. Attitudes and willingness to donate blood among gay and bisexual men in Australia. Transfusion 2020; 60:965-973. [PMID: 32359217 DOI: 10.1111/trf.15768] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2020] [Revised: 02/20/2020] [Accepted: 02/20/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND Men who have sex with men in Australia are currently ineligible to donate blood (are "deferred") for 12 months since last oral or anal sexual contact with another man. In Australia and overseas, there has been limited research on attitudes and perceptions related to blood donation in this population. STUDY DESIGN AND METHODS Questions on blood donation histories and attitudes toward the deferral policy were included in the questionnaire of an online prospective cohort of gay and bisexual men (GBM) living in Australia. RESULTS In 2018, 1595 GBM responded to the survey. In this sample, 28.7% reported previously donating blood. Among the remaining men who had never donated blood, 64.5% expressed an interest in doing so. Nearly all men indicated they were not willing to abstain from sex with another man for 12 months in order to donate, and the vast majority believed the rule was unfair, too strict, and homophobic. Three-quarters (77.7%) said that if the policy changed, they would likely donate blood. Age and openness about one's sexuality were independently associated with one's willingness to donate blood in the absence of the deferral. CONCLUSION There was a high level of willingness and desire to donate blood among GBM. However, rather than abstaining from sex in order to donate, many men comply with the deferral policy and do not donate. A less conservative deferral policy may increase donations from GBM.
Collapse
Affiliation(s)
- Shawn Clackett
- Kirby Institute, UNSW Sydney, Kensington, New South Wale, Australia
| | - Clive R Seed
- Australian Red Cross Lifeblood, Perth, Western Australia, Australia
| | - Garrett Prestage
- Kirby Institute, UNSW Sydney, Kensington, New South Wale, Australia
| | | | - Veronica Hoad
- Australian Red Cross Lifeblood, Perth, Western Australia, Australia
| | - Peter Saxton
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - Bridget Haire
- Kirby Institute, UNSW Sydney, Kensington, New South Wale, Australia
| | - Martin Holt
- Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia
| | - Fengyi Jin
- Kirby Institute, UNSW Sydney, Kensington, New South Wale, Australia
| | - Adam Bourne
- Australian Research Centre in Sex, Health & Society, La Trobe University, Melbourne, Victoria, Australia
| | - Lisa Maher
- Kirby Institute, UNSW Sydney, Kensington, New South Wale, Australia
| | - John Kaldor
- Kirby Institute, UNSW Sydney, Kensington, New South Wale, Australia
| |
Collapse
|
13
|
Quinn B, Pearson R, Cutts J, Seed C, Scott N, Hoad V, Dietze P, Wilson D, Maher L, Thompson A, Farrell M, Harrod M, Caris S, Pink J, Kotsiou G, Hellard M. Blood donation amongst people who inject drugs in Australia: research supporting policy change. Vox Sang 2020; 115:162-170. [PMID: 32023663 DOI: 10.1111/vox.12891] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Revised: 12/23/2019] [Accepted: 01/07/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND OBJECTIVES Until recently, people in Australia with a history of injection drug use (IDU) were deferred indefinitely from donating blood. Knowledge gaps regarding policy non-compliance and the prevalence of blood donation practices amongst people who inject drugs (PWID) precluded changes to this policy. We sought to address these gaps and to estimate the additional risk to Australia's blood supply associated with changing the indefinite deferral policy to 1 or 5 years since last injecting episode. MATERIALS AND METHODS Data on blood donation amongst PWID were collected from 1853 interviews across two Australian studies of PWID conducted during 2015/16. Mathematical modelling was used to estimate the additional risk of hepatitis C (HCV)-infected window period collections as a result of changing the deferral policy. RESULTS A very few (2-4%) study participants reported ever donating blood after ≥1 IDU episode. Changing the deferral policy from indefinite to 1 or 5 years was estimated to result in an additional 0·00000070 (95%CI: 0·00000033-0·00000165) or 0·00000020 (95%CI: 0·00000008-0·00000041) HCV-positive window period collections per year, respectively. CONCLUSION Changing Australia's indefinite deferral period to 1 or 5 years since last injecting episode poses a negligible increase in the risk of HCV-infected window period collections from blood donors with a history of IDU. Our results informed a successful submission to the Australian regulator to change the deferral period from indefinite to 5 years since last injecting episode, a policy which came into effect in September 2018.
Collapse
Affiliation(s)
- Brendan Quinn
- Burnet Institute, Melbourne, Vic., Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia
| | - Ruth Pearson
- Burnet Institute, Melbourne, Vic., Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia
| | - Julia Cutts
- Burnet Institute, Melbourne, Vic., Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia
| | - Clive Seed
- Australian Red Cross Blood Service, Perth, WA, Australia
| | - Nick Scott
- Burnet Institute, Melbourne, Vic., Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia
| | - Veronica Hoad
- Australian Red Cross Blood Service, Perth, WA, Australia
| | - Paul Dietze
- Burnet Institute, Melbourne, Vic., Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia
| | | | - Lisa Maher
- Burnet Institute, Melbourne, Vic., Australia.,Kirby Institute, UNSW, Sydney, NSW, Australia
| | - Alexander Thompson
- Department of Gastroenterology, St Vincent's Hospital and the University of Melbourne (UoM), Fitzroy, Vic., Australia.,Doherty Institute and Melbourne School of Population and Global Health, UoM, Melbourne, Vic., Australia
| | - Michael Farrell
- National Drug and Alcohol Research Centre (NDARC), UNSW, Randwick, NSW, Australia
| | - Mary Harrod
- Australian Injecting and Illicit Drug Users League (AIVL), Canberra, ACT, Australia
| | - Sharon Caris
- Haemophilia Foundation Australia, Malvern East, Vic., Australia
| | - Joanne Pink
- Australian Red Cross Blood Service, Perth, WA, Australia
| | - George Kotsiou
- Australian Red Cross Blood Service, Perth, WA, Australia
| | - Margaret Hellard
- Burnet Institute, Melbourne, Vic., Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia.,Infectious Diseases Department, Alfred Hospital, Melbourne, Vic., Australia
| |
Collapse
|
14
|
Seed CR, Allain J, Lozano M, Laperche S, Gallian P, Gross S, Kwon S, Oh E, Kim J, Chua SS, Lam S, Ang AL, Tsoi W, Hewitt PE, Davison KL, Tettmar K, O'Flaherty N, Boland F, Williams P, Pomeroy L, Wendel S, Fachini R, Scuracchio P, Carminato P, Fearon M, O'Brien SF, Delage G, Kiely P, Hoad V, Matsubayashi K, Satake M, Taira R, Stramer SL, Sauleda S, Bes M, Piron M, El Ekiaby M, Vermeulen M, Levičnik Stezinar S, Nograšek P, Jarvis LM, Petrik J, Charlewood R, Flanagan P, Grabarczyk P, Kopacz A, Łętowska M, Seifried E, Schmidt M. International Forum on Occult hepatitis B infection and transfusion safety. Vox Sang 2019; 114:e1-e35. [DOI: 10.1111/vox.12743] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
| | | | | | - Syria Laperche
- Institut National de la Transfusion Sanguine Département des agents transmissibles par le sang Centre National de Référence Risques Infectieux Transfusionnels 6 rue Alexandre Cabanel Paris 75015 France
| | - Pierre Gallian
- Etablissement Français du Sang 20 Avenue du Stade de France La Plaine Saint‐Denis 93218 France
| | - Sylvie Gross
- Etablissement Français du Sang 20 Avenue du Stade de France La Plaine Saint‐Denis 93218 France
| | - So‐Yong Kwon
- Jungbu Blood Laboratory Center Korean Red Cross 22 Songchonam‐ro, Daedeok‐gu Daejeon Korea
| | - E.Y. Oh
- Jungbu Blood Laboratory Center Korean Red Cross 22 Songchonam‐ro, Daedeok‐gu Daejeon Korea
| | - J.N. Kim
- Division of Human Blood Safety Surveillance Korea Centers for Disease Control and Prevention Osong Korea
| | - Sze Sze Chua
- Health Sciences Authority Blood Services Group 11 Outram Road Singapore 169078 Singapore
| | - Sally Lam
- Health Sciences Authority Blood Services Group 11 Outram Road Singapore 169078 Singapore
| | - Ai Leen Ang
- Health Sciences Authority Blood Services Group 11 Outram Road Singapore 169078 Singapore
| | - Wai‐Chiu Tsoi
- Hong Kong Red Cross Blood Transfusion Service 15 King's Park Rise Kowloon Hong Kong China
| | | | - Katy L. Davison
- NHS Blood and Transplant Public Health England Epidemiology Unit Colindale Avenue Colindale UK
| | - Kate Tettmar
- NHS Blood and Transplant Colindale Centre Charcot Road Colindale UK
| | - Niamh O'Flaherty
- Irish Blood Transfusion Service National Blood Centre St. James's Gate Dublin 8 Ireland
| | - Fiona Boland
- Irish Blood Transfusion Service National Blood Centre St. James's Gate Dublin 8 Ireland
| | - Padraig Williams
- Irish Blood Transfusion Service National Blood Centre St. James's Gate Dublin 8 Ireland
| | - Louise Pomeroy
- Irish Blood Transfusion Service National Blood Centre St. James's Gate Dublin 8 Ireland
| | - Silvano Wendel
- Hospital Sirio Libanês Rua Adma Jafet 91 São Paulo 01308‐050 Brasil
| | - Roberta Fachini
- Hospital Sirio Libanês Rua Adma Jafet 91 São Paulo 01308‐050 Brasil
| | | | | | | | | | - Gilles Delage
- Héma Québec 4045 boul. Cote‐Vertu ville Saint Laurent QC Canada
| | - Philip Kiely
- Australian Red Cross Blood Service 100‐154 Batman Street West Melbourne VIC 3003 Australia
| | - Veronica Hoad
- Australian Red Cross Blood Service 290 Wellington Street Perth WA 6000 Australia
| | - Keiji Matsubayashi
- Central Blood Institute Blood Service Headquarters Japanese Red Cross Society 2‐1‐67 Tatsumi, Koto‐ku Tokyo Japan
| | - Masahiro Satake
- Central Blood Institute Blood Service Headquarters Japanese Red Cross Society 2‐1‐67 Tatsumi, Koto‐ku Tokyo Japan
| | - Rikizo Taira
- Technical Department Blood Service Headquarters Japanese Red Cross Society 1‐2‐1 Shibakoen, Minato‐ku Tokyo Japan
| | | | - Silvia Sauleda
- Transfusion Safety Laboratory Banc de Sang i Teixits Doctor Frederic Duran i Jorda Building, Passeig Taulat, 116 08005 Barcelona Spain
| | - Marta Bes
- Transfusion Safety Laboratory Banc de Sang i Teixits Doctor Frederic Duran i Jorda Building, Passeig Taulat, 116 08005 Barcelona Spain
| | - Maria Piron
- Transfusion Safety Laboratory Banc de Sang i Teixits Doctor Frederic Duran i Jorda Building, Passeig Taulat, 116 08005 Barcelona Spain
| | - Magdy El Ekiaby
- Shabrawishi Hospital Blood Transfusion Centre Finni Square Dokki, Giza Egypt
| | - Marion Vermeulen
- The South African National Blood Service 1 Constantia Boulevard, ConstantiaKloof Roodepoort, Gauteng South Africa
| | | | - Polona Nograšek
- Blood Transfusion Centre of Slovenia Šlajmerjeva 6 SI‐1000 Ljubljana Slovenia
| | - Lisa M. Jarvis
- Scottish National Blood Transfusion Service The Jack Copland Centre 52 Research Avenue North Edinburgh EH14 4BE UK
| | - Juraj Petrik
- Scottish National Blood Transfusion Service The Jack Copland Centre 52 Research Avenue North Edinburgh EH14 4BE UK
| | - Richard Charlewood
- New Zealand Blood Service 71 Great South Road Epsom, Auckland New Zealand
| | - Peter Flanagan
- New Zealand Blood Service 71 Great South Road Epsom, Auckland New Zealand
| | - Piotr Grabarczyk
- Department of Virology Institute of Hematology and Transfusion Medicine Gandhi Str. 14th 02 776 Warsaw Poland
| | - Aneta Kopacz
- Department of Virology Institute of Hematology and Transfusion Medicine Gandhi Str. 14th 02 776 Warsaw Poland
| | - Magdalena Łętowska
- Department of Transfusion Institute of Hematology and Transfusion Medicine Gandhi Str. 14th 02 776 Warsaw Poland
| | - Erhard Seifried
- German Red Cross Institute for Transfusion medicine and Immunohematology German Red Cross Baden‐Wuerrtemberg – Hesse Goethe University Frankfurt Sandhof Street 1 60528 Frankfurt
| | - Michael Schmidt
- German Red Cross Institute for Transfusion medicine and Immunohematology German Red Cross Baden‐Wuerrtemberg – Hesse Goethe University Frankfurt Sandhof Street 1 60528 Frankfurt
| |
Collapse
|
15
|
Jayawardena T, Hoad V, Styles C, Seed C, Bentley P, Clifford V, Lacey S, Gastrell T. Modelling the risk of transfusion-transmitted syphilis: a reconsideration of blood donation testing strategies. Vox Sang 2018; 114:107-116. [PMID: 30565234 DOI: 10.1111/vox.12741] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Revised: 10/08/2018] [Accepted: 11/20/2018] [Indexed: 02/01/2023]
Abstract
BACKGROUND AND OBJECTIVES Donor syphilis testing began in the 1940s amidst widespread transfusion-transmitted syphilis (TTS). Since then, the introduction of penicillin, pre-donation screening questionnaires and improved storage conditions have contributed to reducing transmission risk. Consequently, universal testing may no longer be cost-effective. This study analysed alternative options for donor syphilis testing to determine the optimal strategy. MATERIALS AND METHODS A model was developed using conservative parameter estimates for factors affecting TTS and 2009-2015 Australian donations to calculate risk outcomes (TTS infections, tertiary syphilis in recipients and transfusion-associated congenital syphilis) and cost-effectiveness of alternative testing strategies. The strategies modelled were as follows: universal testing, targeted-testing of high-risk groups (males ≤50 years old and first-time donors) and no testing. RESULTS The estimated risk of TTS is one in 49·5 million transfusions for universal testing, one in 6 million for targeted-testing of males ≤50 years old, one in 4 million for targeted-testing of first-time donors and one in 2·8 million for no testing. For all strategies, the risk of tertiary and congenital syphilis is <1 in 100 million. Universal testing is the least cost-effective strategy with an incremental cost-effectiveness ratio (ICER) estimated at $538·5 million per disability-adjusted life year averted. CONCLUSION Universal testing is not required to maintain the risk of TTS within tolerable limits and is estimated to greatly exceed acceptable ICERs for blood safety interventions. However, despite a strong economic and risk-based rationale, given the epidemiology of syphilis in Australia is changing, feedback from critical stakeholders is not currently supportive of reducing testing.
Collapse
Affiliation(s)
- Thisuri Jayawardena
- Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia
| | - Veronica Hoad
- Australian Red Cross Blood Service, Perth, WA, Australia
| | - Claire Styles
- Australian Red Cross Blood Service, Perth, WA, Australia
| | - Clive Seed
- Australian Red Cross Blood Service, Perth, WA, Australia
| | - Peter Bentley
- Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia.,Australian Red Cross Blood Service, Perth, WA, Australia
| | | | - Sarina Lacey
- Centre for International Economics, Sydney, NSW, Australia
| | - Tessa Gastrell
- Centre for International Economics, Sydney, NSW, Australia
| |
Collapse
|
16
|
Shrestha AC, Flower RL, Seed CR, Keller AJ, Hoad V, Harley R, Leader R, Polkinghorne B, Furlong C, Faddy HM. Hepatitis E virus infections in travellers: assessing the threat to the Australian blood supply. Blood Transfus 2017; 15:191-198. [PMID: 27483488 PMCID: PMC5448823 DOI: 10.2450/2016.0064-16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 05/17/2016] [Indexed: 01/15/2023]
Abstract
BACKGROUND In many developed countries hepatitis E virus (HEV) infections have occurred predominantly in travellers to countries endemic for HEV. HEV is a potential threat to blood safety as the virus is transfusion-transmissible. To minimise this risk in Australia, individuals diagnosed with HEV are deferred. Malarialdeferrals, when donors are restricted from donating fresh blood components following travel toanareain which malaria is endemic, probably also decrease the HEV risk, by deferring donors who travel to many countries also endemic for HEV. The aim of this study is to describe overseas-acquired HEV cases in Australia, in order to determine whether infection in travellers poses a risk to Australian blood safety. MATERIALS AND METHODS Details of all notified HEV cases in Australia from 2002 to 2014 were accessed, and importation rates estimated. Countries in which HEV was acquired were compared to those for which donations are restricted following travel because of a malaria risk. RESULTS Three hundred and thirty-two cases of HEV were acquired overseas. Travel to India accounted for most of these infections, although the importation rate was highest for Nepal and Bangladesh. Countries for which donations are restricted following travel due to malaria risk accounted for 94% of overseas-acquired HEV cases. DISCUSSION The vast majority of overseas-acquired HEV infections were in travellers returning from South Asian countries, which are subject to donation-related travel restrictions for malaria. This minimises the risk HEV poses to the Australian blood supply.
Collapse
Affiliation(s)
- Ashish C. Shrestha
- Research and Development, Australian Red Cross Blood Service, Kelvin Grove, QLD, Australia
- School of Medicine, The University of Queensland, Herston, QLD, Australia
| | - Robert L.P. Flower
- Research and Development, Australian Red Cross Blood Service, Kelvin Grove, QLD, Australia
| | - Clive R. Seed
- Medical Services, Australian Red Cross Blood Service, Perth, WA, Australia
| | - Anthony J. Keller
- Medical Services, Australian Red Cross Blood Service, Perth, WA, Australia
| | - Veronica Hoad
- Medical Services, Australian Red Cross Blood Service, Perth, WA, Australia
| | - Robert Harley
- Medical Services, Australian Red Cross Blood Service, Kelvin Grove, QLD, Australia
| | - Robyn Leader
- OzFoodNet, Office of Health Protection, Australian Government Department of Health, Canberra, Australia
| | - Ben Polkinghorne
- OzFoodNet, Office of Health Protection, Australian Government Department of Health, Canberra, Australia
| | - Catriona Furlong
- OzFoodNet, New South Wales Department of Health, Sydney, Australia
| | - Helen M. Faddy
- Research and Development, Australian Red Cross Blood Service, Kelvin Grove, QLD, Australia
- School of Medicine, The University of Queensland, Herston, QLD, Australia
| |
Collapse
|
17
|
Shrestha AC, Flower RL, Seed CR, Keller AJ, Harley R, Chan HT, Hoad V, Warrilow D, Northill J, Holmberg JA, Faddy HM. Hepatitis E virus RNA in Australian blood donations. Transfusion 2016; 56:3086-3093. [DOI: 10.1111/trf.13799] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Revised: 06/16/2016] [Accepted: 07/17/2016] [Indexed: 12/23/2022]
Affiliation(s)
- Ashish C. Shrestha
- Research and Development; The University of Queenslan; Brisbane Queensland Australia
- School of Medicine; The University of Queenslan; Brisbane Queensland Australia
| | - Robert L.P. Flower
- Research and Development; The University of Queenslan; Brisbane Queensland Australia
| | - Clive R. Seed
- Medical Services; Australian Red Cross Blood Servic; Brisbane Queensland Australia
| | - Anthony J. Keller
- Medical Services; Australian Red Cross Blood Servic; Brisbane Queensland Australia
| | - Robert Harley
- Medical Services; Australian Red Cross Blood Servic; Brisbane Queensland Australia
| | - Hiu-Tat Chan
- Medical Services; Australian Red Cross Blood Servic; Brisbane Queensland Australia
| | - Veronica Hoad
- Medical Services; Australian Red Cross Blood Servic; Brisbane Queensland Australia
| | - David Warrilow
- Public Health Virology Laboratory, Forensic and Scientific Services; Queensland Healt; Brisbane Queensland Australia
| | - Judith Northill
- Public Health Virology Laboratory, Forensic and Scientific Services; Queensland Healt; Brisbane Queensland Australia
| | | | - Helen M. Faddy
- Research and Development; The University of Queenslan; Brisbane Queensland Australia
- School of Medicine; The University of Queenslan; Brisbane Queensland Australia
| |
Collapse
|
18
|
Hoad V, Bentley P, Bell B, Pathak P, Chan HT, Keller A. The infectious disease blood safety risk of Australian hemochromatosis donations. Transfusion 2016; 56:2934-2940. [PMID: 27662424 DOI: 10.1111/trf.13802] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 07/14/2016] [Accepted: 07/17/2016] [Indexed: 12/12/2022]
Abstract
BACKGROUND It has been suggested that blood donors with hereditary hemochromatosis may pose an increased infectious disease risk and adversely affect recipient outcomes. This study compares the infectious disease risk of whole blood (WB) donors enrolled as therapeutic (T) donors to voluntary WB donors to evaluate the safety of blood products provided by the T donors. STUDY DESIGN AND METHODS This was a retrospective cohort study of all WB donations at the Australian Red Cross Blood Service who donated between January 1, 2011, and December 31, 2013, comparing a yearly mean of 11,789 T donors with 107,773 total donations and a yearly mean of 468,889 voluntary WB donors with 2,584,705 total donations. We compared postdonation notification of infectious illnesses, bacterial contamination screening results, and positive tests for blood borne viruses in T and WB donors. RESULTS Rates of transfusion-transmissible infections in donations destined for component manufacture were significantly lower in therapeutic donations compared to voluntary donations (8.4 vs. 21.6 per 100,000 donations). Bacterial contamination (43.0 vs. 45.9 per 100,000 donations) and postdonation illness reporting (136.2 vs. 110.8 per 100,000 donations) were similar in both cohorts. CONCLUSIONS The Australian therapeutic venisection program enables T donors to provide a safe and acceptable source of donated WB that has a low infectious disease risk profile.
Collapse
Affiliation(s)
- Veronica Hoad
- Australian Red Cross Blood Service, Perth, Western Australia, Australia
| | - Peter Bentley
- Australian Red Cross Blood Service, Perth, Western Australia, Australia
| | - Barbara Bell
- Australian Red Cross Blood Service, Perth, Western Australia, Australia
| | - Praveen Pathak
- Australian Red Cross Blood Service, Perth, Western Australia, Australia
| | - Hiu Tat Chan
- Australian Red Cross Blood Service, Perth, Western Australia, Australia
| | - Anthony Keller
- Australian Red Cross Blood Service, Perth, Western Australia, Australia
| |
Collapse
|
19
|
Bentley P, Bell B, Hoad V, Pathak P. The High Ferritin App: electronic referral to the Australian Red Cross Blood Service for therapeutic venesection. Transfus Med 2015; 25:280-1. [PMID: 26286465 DOI: 10.1111/tme.12232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Revised: 06/29/2015] [Accepted: 07/30/2015] [Indexed: 11/29/2022]
Affiliation(s)
- P Bentley
- Australian Red Cross Blood Service, Perth, Australia
| | - B Bell
- Australian Red Cross Blood Service, Perth, Australia
| | - V Hoad
- Australian Red Cross Blood Service, Perth, Australia
| | - P Pathak
- Australian Red Cross Blood Service, Perth, Australia
| |
Collapse
|
20
|
Hoad V, Hayward C. Student Aboriginal health worker smoking: findings from a training college in Western Australia. Aust N Z J Public Health 2012; 36:296-7. [DOI: 10.1111/j.1753-6405.2012.00877.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
21
|
Hoad V, Somerford P, Katzenellenbogen J. High body mass index overtakes tobacco as the leading independent risk factor contributing to disease burden in Western Australia. Aust N Z J Public Health 2010; 34:214-5. [PMID: 23331368 DOI: 10.1111/j.1753-6405.2010.00509.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|